Onyx Announces Pricing of Public Offering
21 June 2007 - 10:00PM
PR Newswire (US)
EMERYVILLE, Calif., June 21 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced the pricing of
its public offering of 6,600,000 shares of its common stock at a
public offering price of $28.00 per share. The company expects to
complete the sale of these shares on or about June 26, 2007. The
company has granted the underwriters a 30-day option to purchase
990,000 additional shares of common stock to cover over-allotments,
if any. Morgan Stanley & Co. Incorporated and Merrill Lynch
& Co. are acting as joint book running managers. Morgan Stanley
& Co. Incorporated, Merrill Lynch & Co., J.P. Morgan
Securities Inc. and Banc of America Securities LLC are acting as
the underwriters. Copies of the final prospectus supplement and
accompanying prospectus relating to this offering may be obtained
from Morgan Stanley & Co. Incorporated (180 Varick Street, New
York, NY 10014 Attn: Prospectus Department or by email at ),
Merrill Lynch & Co. (Attn: Prospectus Department, 4 World
Financial Center, New York, New York 10080) or from Onyx
Pharmaceuticals, Inc. (2100 Powell Street, Emeryville, CA 94608,
fax 510-597-6600). The offering is being made pursuant to an
effective automatic shelf registration statement. This press
release shall not constitute an offer to sell or the solicitation
of an offer to buy nor shall there be any sale of these securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. About Onyx
Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a
biopharmaceutical company developing innovative therapies that
target the molecular mechanisms that cause cancer. The company is
developing Nexavar(R), a small molecule drug, with Bayer HealthCare
Pharmaceuticals Inc. Nexavar is approved for the treatment of
advanced kidney cancer in more than 50 countries. Nexavar(R)
(sorafenib) tablets is a registered trademark of Bayer HealthCare
Pharmaceuticals Inc. Forward Looking Statements This news release
contains "forward-looking statements" of Onyx within the meaning of
the federal securities laws. These forward-looking statements
include without limitation, statements regarding expectations as to
the completion of the public offering. These statements are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated. Reference
should be made to Onyx's Annual Report on Form 10-K for the year
ended December 31, 2006, filed with the Securities and Exchange
Commission under the heading "Risk Factors" for a more detailed
description of such factors, as well as the Company's subsequent
quarterly report on Form 10-Q. Readers are cautioned not to place
undue reliance on these forward-looking statements that speak only
as of the date of this release. Onyx undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events, or circumstances after the date of this
release except as required by law. DATASOURCE: Onyx
Pharmaceuticals, Inc. CONTACT: Julie Wood, Vice President, Investor
Relations, +1-510-597-6505, or Greg Schafer, Chief Financial
Officer, +1-510-597-6684, both of Onyx Pharmaceuticals, Inc.
Copyright
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More Onyx Pharmaceuticals (MM) News Articles